65,437 trials
Healthy
Primary: Serum Polyphenol Concentrations Over 24h From Food Consumption — 1.7; 12.1; 7.7; 0.01 nmol*h/L — p=0.02
Facial Rhytides
Primary: Average Total Dose Per Treatment Period — 49.2; 48.1; 45.8 Units
Liver Diseases
Primary: Number of Participants With Improvement in Non-alcoholic Fatty Liver Disease (NAFLD) Activity Defined by Change in Standardized Scoring of Liver Biopsies at Baseline and…
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Primary: Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set) — -32.8; -47.2 percent change
Rheumatoid Arthritis
Primary: Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520 — 187 participants
Genital Herpes · HIV Infection
Primary: The Quantity of HIV-1 RNA in Plasma While on 400 mg Twice Daily of Acyclovir Versus 1000 mg Twice Daily of Valacyclovir. — 4.08; 3.68 log10 copies/mL — p=<0.001
Endometrial Carcinoma
Primary: Determination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by…
Rupture of Amniotic Membranes
Primary: Pregnant Women Positive and Negative for Membrane Rupture Measured Via Clinical Assessment, Chart Review and ROM Plus — 95; 88; 160; 187 participants
Intractable Pain
Primary: Demonstrate That Prometra Programmable Pump System Accurately and Safely Delivers Medication in the Intrathecal Space, as Programmed. — 97.8 % of programmed vol…
Epilepsy
Primary: Percentage of Participants Who Were Assessed As Seizure Free — 63.1; 57.6 percentage of participants
Pain · Diabetic Neuropathy
Primary: The Change From Baseline in Mean Diabetic Neuropathy Pain 0-10 Numerical Rating Scale Score at the End of Treatment (Average of Last 7 Days Treatment) — -1.67; -1.55…
Pain, Migraine
Primary: Percent of Subjects Who Are Pain Free at 2 Hours. — 34.7; 44.9; 26.4 Percent of participants
Uveitis
Primary: Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis — 6.0; 3.2…
Symptomatic Contact Lens Wearers
Primary: Likert Statement: When I Use This Solution, I Can Comfortably Wear my Lenses. — 3.9; 3.8 Units on a scale
Androgenetic Alopecia · Hair Loss · Female Pattern Baldness
Primary: Changes in Terminal Hair Count Week 16 and 26 Weeks Over Baseline — 1.3; 14.8; 2.8; 20.2 hairs per cm^2